The Pharmaceutical Journal
Vol 280 No 7495 p352
29 March 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Tysabri liver warnings

Europe wants stronger warnings to be included in the product information for natalizumab (Tysabri). Following a safety review, the European Medicines Agency said there is a need to warn patients and prescribers that liver injury may occur when the multiple sclerosis drug is used. The agency also recommends that patients treated with natalizumab should have their liver function monitored.